Kopozgo (Mavacamten) Capsules

Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.

Obstructive hypertrophic cardiomyopathy is an inherited and often progressive heart disease that can cause symptoms such as shortness of breath, fatigue, and dizziness, and in severe cases lead to heart failure, arrhythmias, stroke, or sudden cardiac death. Affecting nearly 1 in 500 people globally, the condition may impact up to 2.8 million people in India, with nearly 80 to 90 per cent remaining undiagnosed.

Is Kopozgo (Mavacamten) available in India?

Bristol Myers Squibb (BMS) has launched Kopozgo (Mavacamten) in India, the first and only oral, selective cardiac myosin inhibitor approved for adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (oHCM).

How to get Kopozgo Capsules delivered in India?

Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations. Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.

IPN having representation in Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.

Who can help source Kopozgo Capsules in India legally?

Named-patient import facilitator contact details
Company Name: Indian Pharma Network (IPN)
Address: 60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
For sourcing and import coordination of specialty medicines, contact:
Mr. Tarun: +91 9891 296 838
Mr. Neeraj: +91 9811 747 774
Email: info@indianpharmanetwork.co.in

Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.

• Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
• Bristol Myers Squibb launches heart medication Kopozgo in Indian market
• BMS launches selective cardiac myosin inhibitor drug in India

Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India.